NYTIMES (Rebecca Robbins) - Moderna’s Shift to Cancer Company Lifts Stock Up 177%
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.
AI:Moderna's stock has surged 177% following a strategic pivot from COVID-19 vaccines to cancer treatments, specifically targeting melanoma. This massive recovery follows a period of declining revenue caused by the drop in pandemic-related vaccine demand. ❤️❤️❤️Open